新洋豐(000902.SZ):擬投建年產20萬噸磷酸鐵及上游配套項目
格隆匯8月17日丨新洋豐(000902.SZ)公佈,公司作為磷化工行業的龍頭企業,在磷礦--磷酸--磷酸一銨這一產業鏈上具備數十年的積累,建立了強有力的競爭優勢。公司現具有年產180萬噸磷酸一銨的生產能力(含15萬噸工業級磷酸一銨),磷酸一銨產能全國最大,並可根據市場發展需求提高工業級磷酸一銨生產能力。磷酸鐵的製備需要用到工業級磷酸一銨或磷酸,公司在磷酸鐵的生產上具備得天獨厚的優勢。為抓住新能源市場機會,充分利用公司在磷化工行業的經驗與積累,公司擬投資建設年產20萬噸磷酸鐵及上游配套項目。該項目計劃投資總額為人民幣25-30億元,項目資金來源為公司自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.